Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Liu, Z., VanBlargan, L. A., Bloyet, L.-M., Rothlauf, P. W., Chen, R. E., Stumpf, S., Zhao, H., Errico, J. M., Theel, E. S., Liebeskind, M. J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.01.014 · Cited by 725 · see citing works

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E. R., Yu, J., Bahna, F., Bimela, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.005 · Cited by 519 · see citing works

The variant gambit: COVID-19’s next move

Plante, J. A., Mitchell, B. M., Plante, K. S., Debbink, K., Weaver, S. C., & Menachery, V. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.020 · Cited by 328 · see citing works

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Edara, V. V., Norwood, C., Floyd, K., Lai, L., Davis-Gardner, M. E., Hudson, W. H., Mantus, G., Nyhoff, L. E., Adelman, M. W., Fineman, R., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.009 · Cited by 224 · see citing works

Development of a rapid Focus Reduction Neutralization Test Assay for measuring SARS-CoV-2 neutralizing antibodies

Vanderheiden, A., Edara, V., Floyd, K., Kauffman, R. C., Mantus, G., Anderson, E., Rouphael, N., Edupuganti, S., Shi, P.-Y., Menachery, V., et al. (2020) · Current Protocols in Immunology · doi:10.1002/cpim.116 · Cited by 141 · see citing works

Mechanisms of SARS-CoV-2 entry into cells

Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00418-x · Cited by 3,082 · see citing works

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992 · see citing works

The biological and clinical significance of emerging SARS-CoV-2 variants

Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009 · see citing works

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911 · see citing works

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., Triccas, J. A., Khoury, D. S., & Davenport, M. P. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00267-6 · Cited by 590 · see citing works

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O’Dell, S., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 442 · see citing works

Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant

Zhang, J., Xiao, T., Cai, Y., Lavine, C. L., Peng, H., Zhu, H., Anand, K., Tong, P., Gautam, A. K., Mayer, M. L., et al. (2021) · Science · doi:10.1126/science.abl9463 · Cited by 281 · see citing works

Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants

McCallum, M., Walls, A. C., Sprouse, K. R., Bowen, J. E., Rosen, L. E., Dang, H. V., Marco, A. D., Franko, N., Tilles, S. W., Logue, J. K., et al. (2021) · Science · doi:10.1126/science.abl8506 · Cited by 273 · see citing works

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination

Cho, A., Muecksch, F., Schaefer-Babajew, D. J., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., et al. (2021) · Nature · doi:10.1038/s41586-021-04060-7 · Cited by 254 · see citing works

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individualsPreprint

Planas, D., Veyer, D. L., Baidaliuk, A., Staropoli, I., Guivel‐Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.26.445838 · Cited by 272 · see citing works

The germinal centre B cell response to SARS-CoV-2

Laidlaw, B. J., & Ellebedy, A. H. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00657-1 · Cited by 250 · see citing works

Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety

Mascellino, M., Timoteo, F. D., Angelis, M. D., & Oliva, A. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s315727 · Cited by 222 · see citing works

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants

Martínez-Flores, D., Zepeda–Cervantes, J., Cruz-Reséndiz, A., Aguirre‐Sampieri, S., Sampieri, A., & Vaca, L. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701501 · Cited by 237 · see citing works

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Shroff, R. T., Chalasani, P., Wei, R., Pennington, D., Quirk, G., Schoenle, M. V., Peyton, K. L., Uhrlaub, J. L., Ripperger, T. J., Jergović, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01542-z · Cited by 233 · see citing works

SARS-COV-2 Variants: Differences and Potential of Immune Evasion

Hirabara, S. M., Serdan, T. D. A., Gorjão, R., Masi, L. N., Pithon‐Curi, T. C., Covas, D. T., Curi, R., & Durigon, E. L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.781429 · Cited by 216 · see citing works

A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson

Patel, R. S., Kaki, M., Potluri, V., Kahar, P., & Khanna, D. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2002083 · Cited by 225 · see citing works

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant

Edara, V. V., Manning, K. E., Ellis, M. L., Lai, L., Moore, K. M., Foster, S. L., Floyd, K. A., Davis-Gardner, M. E., Mantus, G. E., Nyhoff, L. E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100529 · Cited by 205 · see citing works

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron

Gagné, M., Moliva, J. I., Foulds, K. E., Andrew, S. F., Flynn, B. J., Werner, A. P., Wagner, D. A., Teng, I., Lin, B. C., Moore, C. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.038 · Cited by 206 · see citing works

The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape

Tian, D., Sun, Y., Zhou, J., & Ye, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.751778 · Cited by 192 · see citing works

Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?

Lazarević, I., Pravica, V., Miljanovic, D., & Cupic, M. D. (2021) · Viruses · doi:10.3390/v13071192 · Cited by 188 · see citing works

Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals

(2022) · doi:10.1016/j.cell.2022.01.027 · Cited by 179 · see citing works

Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission

Escalera, A., Gonzalez-Reiche, A. S., Aslam, S., Mena, I., Laporte, M., Pearl, R. L., Fossati, A., Rathnasinghe, R., Alshammary, H., van de Guchte, A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.01.006 · Cited by 169 · see citing works

Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study

Sonabend, R., Whittles, L. K., Imai, N., Perez-Guzman, P. N., Knock, E. S., Rawson, T., Gaythorpe, K. A. M., Djaafara, B. A., Hinsley, W., FitzJohn, R. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02276-5 · Cited by 156 · see citing works

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Lyke, K. E., Atmar, R. L., Islas, C. D., Posavad, C. M., Szydlo, D., Paul Chourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100679 · Cited by 153 · see citing works

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

Oosting, S. F., van der Veldt, A. A. M., GeurtsvanKessel, C. H., Fehrmann, R. S. N., van Binnendijk, R. S., Dingemans, A. C., Smit, E. F., Hiltermann, T. J. N., den Hartog, G., Jalving, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00574-x · Cited by 152 · see citing works

COVID‐19 vaccinations: The unknowns, challenges, and hopes

Mohamed, K., Rzymski, P., Islam, M. S., Makuku, R., Mushtaq, A., Khan, A., Ivanovska, M., Makka, S. A., Hashem, F., Marquez, L. P., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27487 · Cited by 142 · see citing works

SARS‐CoV‐2 variants and vulnerability at the global level

Chavda, V. P., Patel, A., & Vaghasiya, D. D. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27717 · Cited by 132 · see citing works

SARS-CoV-2: Evolution and Emergence of New Viral Variants

Flores-Vega, V. R., Monroy-Molina, J. V., Jiménez-Hernández, L. E., Torres, A. G., Santos, J. I., & Rosales-Reyes, R. (2022) · Viruses · doi:10.3390/v14040653 · Cited by 121 · see citing works

Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner

Keeton, R. S., Richardson, S. I., Moyo-Gwete, T., Hermanus, T., Tincho, M. B., Benede, N., Manamela, N. P., Baguma, R., Makhado, Z., Ngomti, A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.10.003 · Cited by 105 · see citing works

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies

Zhou, H., Tada, T., Dcosta, B. M., & Landau, N. R. (2022) · Viruses · doi:10.3390/v14061334 · Cited by 108 · see citing works

Reinfection in patients with COVID-19: a systematic review

Ren, X., Zhou, J., Guo, J., Hao, C., Zheng, M., Zhang, R., Huang, Q. Y., Yao, X., Li, R., & Jin, Y. (2022) · Global Health Research and Policy · doi:10.1186/s41256-022-00245-3 · Cited by 104 · see citing works

An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines

Hillary, V. E., & Ceasar, S. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13952 · Cited by 112 · see citing works

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern

Dupont, L., Snell, L., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T., Hallett, S. R., Pickering, S., Charalampous, T., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00974-0 · Cited by 98 · see citing works

COVID-19: Challenges of Viral Variants

Jacobs, J. L., Haidar, G., & Mellors, J. W. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-020956 · Cited by 100 · see citing works

Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions

Dhawan, M. K., Sharma, A., Choudhary, P., Thakur, N., Rajkhowa, T. K., & Choudhary, O. P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2068883 · Cited by 104 · see citing works

The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape

Tian, D., Sun, Y., Zhou, J., & Ye, Q. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27376 · Cited by 101 · see citing works

The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far

Chavda, V. P., Bezbaruah, R., Deka, K., Nongrang, L., & Kalita, T. (2022) · Vaccines · doi:10.3390/vaccines10111926 · Cited by 103 · see citing works

Accelerated waning of the humoral response to COVID-19 vaccines in obesity

van der Klaauw, A. A., Horner, E. C., Pereyra-Gerber, P., Agrawal, U., Foster, W. S., Spencer, S., Vergese, B., Smith, M., Henning, E., Ramsay, I. D., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02343-2 · Cited by 102 · see citing works

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience

Peled, Y., Ram, E., Ii Jacob Lavee, I., Segev, A., Matezky, S., Wieder-Finesod, A., Halperin, R., Mandelboim, M., Indenbaum, V., Levy, I., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.08.010 · Cited by 99 · see citing works

Durability of immune responses to mRNA booster vaccination against COVID-19

Arunachalam, P. S., Lai, L., Samaha, H., Feng, Y., Hu, M., Hui, H. S.-Y., Wali, B., Ellis, M. L., Davis-Gardner, M. E., Huerta, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167955 · Cited by 100 · see citing works

Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein

Tortorici, M. A., Walls, A. C., Joshi, A., Park, Y., Eguia, R. T., Miranda, M. C., Kepl, E., Dosey, A. M., Stevens‐Ayers, T., Boeckh, M. J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.019 · Cited by 87 · see citing works

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021

Bozio, C. H., Grannis, S. J., Naleway, A. L., Ong, T. C., Butterfield, K. A., DeSilva, M. B., Natarajan, K., Yang, D., Rao, S., Klein, N. P., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7044e1 · Cited by 91 · see citing works

Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans

Haveri, A., Ekström, N., Solastie, A., Virta, C., Österlund, P., Isosaari, E., Nohynek, H., PALMU, A. A. I., & Melin, M. M. (2021) · European Journal of Immunology · doi:10.1002/eji.202149535 · Cited by 85 · see citing works

Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM

Wang, Y., Xu, C., Wang, Y., Qin, H., Zhang, C., Li, Z., Xu, S., Zuo, Q., Liu, C., Huang, Z. W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27350-0 · Cited by 83 · see citing works

Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers

Moncunill, G., Aguilar, R., Ribes, M., Ortega, N., Rubio, R., Salmerón, G., Molina, M. J., Vidal, M., Barrios, D., Mitchell, R. A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2021.103805 · Cited by 73 · see citing works

A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants

Schmitz, A. J., Turner, J. S., Liu, Z., Zhou, J. Q., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.013 · Cited by 63 · see citing works

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung

Gagné, M., Corbett, K. S., Flynn, B. J., Foulds, K. E., Wagner, D. A., Andrew, S. F., Todd, J.-P. M., Honeycutt, C. C., McCormick, L., Nurmukhambetova, S. T., et al. (2021) · Cell · doi:10.1016/j.cell.2021.12.002 · Cited by 71 · see citing works

A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants

Schmitz, A. J., Turner, J. S., Liu, Z., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., Alsoussi, W. B., et al. (2021) · doi:10.1101/2021.03.24.436864 · Cited by 72 · see citing works

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

Ludwig, H., Sonneveld, P., Facon, T. T. F., Miguel, J. F. S., Avet‐Loiseau, H., Mohty, M., Mateos, M.-V., Moreau, P., Cavo, M., Pawlyn, C., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00278-7 · Cited by 65 · see citing works

SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence

Tatsi, E., Filippatos, F., & Michos, A. G. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821002430 · Cited by 63 · see citing works

B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies

Zhan, Y., Yin, H. Y., & Yin, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.66881 · Cited by 65 · see citing works

Accelerating PERx reaction enables covalent nanobodies for potent neutralization of SARS-CoV-2 and variants

(2022) · doi:10.1016/j.chempr.2022.07.012 · Cited by 64 · see citing works

Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates

Gagné, M., Flynn, B. J., Andrew, S. F., Marquez, J., Flebbe, D. R., Mychalowych, A., Lamb, E., Davis-Gardner, M. E., Burnett, M. R., Serebryannyy, L., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01951-5 · Cited by 73 · see citing works

Antigenic characterization of influenza and SARS-CoV-2 viruses

Wang, Y., Tang, C. Y., & Wan, X. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03806-6 · Cited by 60 · see citing works

The ins and outs of SARS-CoV-2 variants of concern (VOCs)

Salehi-Vaziri, ‪., Fazlalipour, M., Khorrami, S. M. S., Azadmanesh, K., Pouriayevali, M. H., Jalali, T., Shoja, Z., & Maleki, A. (2022) · Archives of Virology · doi:10.1007/s00705-022-05365-2 · Cited by 58 · see citing works

Durability of immune responses to the BNT162b2 mRNA vaccine

Suthar, M. S., Arunachalam, P. S., Hu, M., Reis, N., Trisal, M., Raeber, O., Chinthrajah, R. S., Davis-Gardner, M. E., Manning, K. E., Mudvari, P., et al. (2022) · Med · doi:10.1016/j.medj.2021.12.005 · Cited by 60 · see citing works

SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS, California, USA

Hoffman, S. A., Costales, C., Sahoo, M. K., Palanisamy, S., Yamamoto, F. F., Huang, C., Verghese, M., Solis, D., Sibai, M., Subramanian, A. K., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2710.211461 · Cited by 57 · see citing works

SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters

Mohandas, S., Yadav, P. D., Shete, A. M., Nyayanit, D. A., Sapkal, G. N., Lole, K. S., & Gupta, N. (2021) · Viruses · doi:10.3390/v13091773 · Cited by 56 · see citing works

Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial

Chiuppesi, F., Zaia, J. A., Frankel, P. H., Stan, R., Drake, J., Williams, B., Acosta, A. M., Francis, K., Taplitz, R. A., Dickter, J. K., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00027-1 · Cited by 55 · see citing works

The way of SARS-CoV-2 vaccine development: success and challenges

Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00796-w · Cited by 53 · see citing works

Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine

Arunachalam, P. S., Feng, Y., Ashraf, U., Hu, M., Walls, A. C., Edara, V. V., Zarnitsyna, V. I., Aye, P. P., Golden, N., Miranda, M. C., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4130 · Cited by 51 · see citing works

Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant

Valanparambil, R. M., Carlisle, J. W., Linderman, S. L., Akhtar, A., Millett, R. L., Lai, L., Chang, A., McCook‐Veal, A. A., Switchenko, J. M., Nasti, T. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02986 · Cited by 48 · see citing works

The challenges of COVID‐19 Delta variant: Prevention and vaccine development

He, X., He, C., Hong, W., Zhang, K., & Wei, X. (2021) · MedComm · doi:10.1002/mco2.95 · Cited by 49 · see citing works

COVID‐19: A systematic review and update on prevention, diagnosis, and treatment

Aliabadi, H. A. M., Eivazzadeh‐Keihan, R., Parikhani, A. B., Mehraban, S. F., Maleki, A. R., Fereshteh, S., Bazaz, M., Zolriasatein, A., Bozorgnia, B., Rahmati, S., et al. (2022) · MedComm · doi:10.1002/mco2.115 · Cited by 49 · see citing works

Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England

Mensah, A. A., Campbell, H. J., Stowe, J., Seghezzo, G., Simmons, R., Lacy, J., Bukasa, A., O’Boyle, S., Ramsay, M. E., Brown, K. E., et al. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(22)00059-1 · Cited by 49 · see citing works

Age-associated B cells predict impaired humoral immunity after COVID-19 vaccination in patients receiving immune checkpoint blockade

Yam‐Puc, J. C., Hosseini, Z., Horner, E. C., Gerber, P. P., Covarrubias, N. B., Hughes, R., Lulla, A., Rust, M. A., Boston, R. H., Ali, M. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38810-0 · Cited by 49 · see citing works

Human Organoids and Organs‐on‐Chips for Addressing COVID‐19 Challenges

Wang, Y., Wang, P., & Qin, J. (2022) · Advanced Science · doi:10.1002/advs.202105187 · Cited by 48 · see citing works

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma

Nooka, A. K., Shanmugasundaram, U., Cheedarla, N., Verkerke, H., Edara, V. V., Valanparambil, R. M., Kaufman, J. L., Hofmeister, C. C., Joseph, N. S., Lonial, S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02257 · Cited by 48 · see citing works

Emergence of SARS-CoV-2 Variants in the World: How Could This Happen?

Parra-Lucares, A., Segura, P., Rojas, V. A., Pumarino, C., Saint-Pierre, G., & Toro, L. (2022) · Life · doi:10.3390/life12020194 · Cited by 46 · see citing works

Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses

Balachandran, H., Phetsouphanh, C., Agapiou, D., Adhikari, A., Rodrigo, C., Hammoud, M., Shrestha, L. B., Keoshkerian, E., Gupta, M., Turville, S. G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110345 · Cited by 45 · see citing works

Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Chang, A., Akhtar, A., Linderman, S. L., Lai, L., Orellana-Noia, V. M., Valanparambil, R., Ahmed, H., Zarnitsyna, V. I., McCook-Veal, A. A., Switchenko, J. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00088 · Cited by 45 · see citing works

SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants

Hattab, D., Amer, M. F. A., Al‐Alami, Z. M., & Bakhtiar, A. (2024) · Infection · doi:10.1007/s15010-024-02223-y · Cited by 44 · see citing works

Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses

Tomalka, J. A., Suthar, M. S., Deeks, S. G., & Sékaly, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01130-4 · Cited by 45 · see citing works

Individual genetic variability mainly of Proinflammatory cytokines, cytokine receptors, and toll‐like receptors dictates pathophysiology of COVID‐19 disease

Vakil, M. K., Mansoori, Y., Al‐Awsi, G. R. L., Hosseinipour, A., Ahsant, S., Ahmadi, S., Ekrahi, M., Montaseri, Z., Pezeshki, B., Mohaghegh, P., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27849 · Cited by 42 · see citing works

Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England

Perez-Guzman, P. N., Knock, E., Imai, N., Rawson, T., Santoni, C. N., Alcada, J., Whittles, L. K., Thekke Kanapram, D., Sonabend, R., Gaythorpe, K. A. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39661-5 · Cited by 42 · see citing works

Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera

Rathnasinghe, R., Jangra, S., Ye, C., Čupić, A., Singh, G., Martínez‐Romero, C., Mulder, L. C. F., Kehrer, T., Yildiz, S., Choi, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30763-0 · Cited by 41 · see citing works

The past, current and future epidemiological dynamic of SARS-CoV-2

Balloux, F., Tan, C. C. S., Swadling, L., Richard, D., Jenner, C., Maini, M. K., & van Dorp, L. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac003 · Cited by 37 · see citing works

COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn

Muñoz, F. M., Posavad, C. M., Richardson, B. A., Badell, M. L., Bunge, K. E., Mulligan, M. J., Parameswaran, L., Kelly, C. W., Olson‐Chen, C., Novak, R. M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.032 · Cited by 48 · see citing works

Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2

Liang, Y., Zhang, J., Yuan, R. Y., Wang, M. Y., He, P., Su, J. G., Han, Z. B., Jin, Y. Q., Hou, J. W., Zhang, H., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00383-5 · Cited by 42 · see citing works

The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance

Soh, S. M., Kim, Y., Kim, C., Jang, U. S., & Lee, H.-R. (2021) · The Journal of Microbiology · doi:10.1007/s12275-021-1348-5 · Cited by 37 · see citing works

Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike

Changrob, S., Fu, Y., Guthmiller, J. J., Halfmann, P., Li, L., Stamper, C. T., Dugan, H. L., Accola, M., Rehrauer, W., Zheng, N.-Y., et al. (2021) · mBio · doi:10.1128/mbio.02975-21 · Cited by 39 · see citing works

Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

Mantus, G. E., Nyhoff, L. E., Edara, V. V., Zarnitsyna, V. I., Ciric, C. R., Flowers, M. W., Norwood, C., Ellis, M. L., Hussaini, L., Manning, K. E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100603 · Cited by 37 · see citing works

Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination

Cho, A., Muecksch, F., Schaefer-Babajew, D., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., et al. (2021) · doi:10.1101/2021.07.29.454333 · Cited by 275 · see citing works

SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire

Tarke, A., Ramezani-Rad, P., Neto, T. A. P., Lee, Y., Silva‐Moraes, V., Goodwin, B., Bloom, N. I., Siddiqui, L., Avalos, L., Frazier, A., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101583 · Cited by 37 · see citing works

Nanotechnology for the management of COVID-19 during the pandemic and in the post-pandemic era

Xu, C., Lei, C., Hosseinpour, S., Ivanovski, S., Walsh, L. J., & Khademhosseini, A. (2022) · National Science Review · doi:10.1093/nsr/nwac124 · Cited by 38 · see citing works

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies

Focosi, D., Tuccori, M., Baj, A., & Maggi, F. (2021) · Viruses · doi:10.3390/v13071211 · Cited by 37 · see citing works

Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia

Parry, H., McIlroy, G., Bruton, R. K., Damery, S. L., Tyson, G. B., Logan, N. A., Davis, C., Willett, B. J., Zuo, J., Ali, M., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01219-7 · Cited by 35 · see citing works

Serological Cross-Reactivity in Zoonotic Flaviviral Infections of Medical Importance

da Silva, P. G., dos Reis, J. A. S., Rodrigues, M. N., Ardaya, Q. D. S., & Mesquita, J. R. (2023) · Antibodies · doi:10.3390/antib12010018 · Cited by 35 · see citing works

SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity

Neerukonda, S. N., Vassell, R. A., Lusvarghi, S., Wang, R., Echegaray, F., Bentley, L., Eakin, A. E., Erlandson, K. J., Katzelnick, L. C., Weiss, C. D., et al. (2021) · Viruses · doi:10.3390/v13122485 · Cited by 30 · see citing works

SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern

Hawman, D. W., Meade-White, K., Archer, J. F., Leventhal, S. S., Wilson, D., Shaia, C., Randall, S., Khandhar, A. P., Krieger, K., Hsiang, T.-Y., et al. (2022) · eLife · doi:10.7554/elife.75537 · Cited by 34 · see citing works

COVID-19: Epidemiologie und Mutationen

Hemmer, C. J., Löbermann, M., & Reisinger, E. C. (2021) · Der Radiologe · doi:10.1007/s00117-021-00909-0 · Cited by 33 · see citing works

The Immune Response to SARS-CoV-2 and Variants of Concern

Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 32 · see citing works

The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines

Jiang, Y., Wu, Q. Y., Song, P., & You, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.806641 · Cited by 34 · see citing works

Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

Azeem, M. I., Nooka, A. K., Shanmugasundaram, U., Cheedarla, N., Potdar, S. V., Manalo, R. J., Moreno, A., Switchenko, J. M., Cheedarla, S., Doxie, D. B., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0173 · Cited by 31 · see citing works

Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers

Jantarabenjakul, W., Chantasrisawad, N., Puthanakit, T., Wacharapluesadee, S., Hirankarn, N., Ruenjaiman, V., Paitoonpong, L., Suwanpimolkul, G., Torvorapanit, P., Pradit, R., et al. (2021) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-250721-1197 · Cited by 31 · see citing works

The intestinal microbiota and improving the efficacy of COVID-19 vaccinations

Chen, J., Vitetta, L., Henson, J. D., & Hall, S. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104850 · Cited by 32 · see citing works

Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease‐19 pandemic

Chadha, J., Khullar, L., & Mittal, N. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15687 · Cited by 32 · see citing works

Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases

Petrone, L., Diamanti, A. P., Sebastiani, G. D., Aiello, A., Laganà, B., Cuzzi, G., Vanini, V., Gualano, G., Grifoni, A., Ferraioli, M., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.04.027 · Cited by 32 · see citing works

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2

Yuan, Y., Zhang, X., Chen, R., Li, Y., Wu, B., Li, R., Zou, F., Ma, X., Wang, X., Chen, Q., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110256 · Cited by 31 · see citing works

Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting

Hauser, B. M., Sangesland, M., Denis, K. S., Lam, E. C., Case, J. B., Windsor, I. W., Feldman, J. E., Caradonna, T. M., Kannegieter, T., Diamond, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110561 · Cited by 37 · see citing works

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697 · see citing works

Neutralization of B.1.617.2 variant through antibodies elicited by ChAdOx1‐S, BBIBP‐CorV, and Gam‐COVID‐Vac in an Argentinean cohort

Blanco, S., Aguilar, J. J., Spinsanti, L., Díaz, A., Beranek, M., Rivarola, M. E., Fernández, E. A., Mangeaud, A. P., Konigheim, B. S., & Gallego, S. V. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28286

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variantPreprint

Edara, V. V., Lai, L., Sahoo, M. K., Floyd, K. A., Sibai, M., Solis, D., Flowers, M. W., Hussaini, L., Ciric, C. R., Bechnak, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.09.443299 · Cited by 100 · see citing works

Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination

Bonura, F., Genovese, D., Amodio, E., Calamusa, G., Sanfilippo, G. L., Cacioppo, F., Giammanco, A., Grazia, S. D., & Ferraro, D. (2022) · Vaccines · doi:10.3390/vaccines10060874 · Cited by 7 · see citing works

In vitro neutralizing activity of BNT162b2 mRNA‐induced antibodies against full B.1.351 SARS‐CoV‐2 variant

Serrano‐Conde, E., Leyva, A., Fuentes, A. P., de Salazar, A., Chueca, N., Pérez‐Castro, S., Regueiro, B. J., Rojas, A., Mendoza, J., Rojas, J., et al. (2021) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14417 · Cited by 3 · see citing works